Table 2.
Pharmacokinetic and pharmacodynamic parameters obtained by the model analysis for the interaction between SJW and CsA
| Imax | 2.61 ± 1.80 | |
| Km (mg day−1) | 428 (100.2–1828)* | |
| ke (month−1) | 4.72 ± 1.42 | |
| α · Ks0 ((mg day−1)/ (ng ml−1)/month) | Case 1 | 5.53 ± 1.42 |
| Case 2 | 5.05 ± 1.62 | |
| Case 3 | 3.33 ± 1.03 | |
| Case 4 | 5.20 ± 1.61 | |
| Case 5 | 5.09 ± 1.69 | |
| Case 6 | 10.0 ± 3.75 | |
| Case 7 | 6.58 ± 2.31 | |
| Case 8 | 8.10 ± 2.65 | |
| Case 9 | 6.92 ± 2.11 |
Estimate ± SD.
*
range Imax: maximal induction potency of SJW for P.Km: the dose of SJW required for half-maximal induction (mg day−1). ke: the elimination rate constant of the detoxicating proteins (/month). α: a constant ((mg day−1)/(ng ml−1)/AU). Ks0: the synthesis rate constant of detoxicating proteins in the absence of SJW (AU/month).